Skip to main content
eScholarship
Open Access Publications from the University of California

Rapid progression of prostate cancer in men with a BRCA2 mutation.

  • Author(s): Narod, SA
  • Neuhausen, S
  • Vichodez, G
  • Armel, S
  • Lynch, HT
  • Ghadirian, P
  • Cummings, S
  • Olopade, O
  • Stoppa-Lyonnet, D
  • Couch, F
  • Wagner, T
  • Warner, E
  • Foulkes, WD
  • Saal, H
  • Weitzel, J
  • Tulman, A
  • Poll, A
  • Nam, R
  • Sun, P
  • Hereditary Breast Cancer Study Group
  • Danquah, Jessica
  • Domchek, Susan
  • Tung, Nadine
  • Ainsworth, Peter
  • Horsman, Douglas
  • Kim-Sing, Charmaine
  • Maugard, Christine
  • Eisen, Andrea
  • Daly, Mary
  • McKinnon, Wendy
  • Wood, Marie
  • Isaacs, Claudine
  • Gilchrist, Dawna
  • Karlan, Beth
  • Nedelcu, Raluca
  • Meschino, Wendy
  • Garber, Judy
  • Pasini, Barbara
  • Manoukian, Siranoush
  • Bellati, Christina
  • et al.
Abstract

Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View